Avac Event
On October 5, The Choice Agenda (TCA) and the National Coalition of STD Directors (NCSD) hosted a discussion on the roll out of Doxycycline as STI PEP for helping gay, bisexual, and other men who have sex with men and transgender women reduce bacterial STIs, including gonorrhea, chlamydia, and syphilis.
Speakers:
Dr. Taimur Khan, Fenway Health
Cait Shea, NCSD
Kendrick Clack, NP, Crofoot MD Clinic/Research Center
Lee Vaughn-Ogin, Bigger Blacker Book
This report, by M&C Saatchi World Services, AVAC, and partners, highlights learnings from Human-Centered Design Research undertaken in 2022 to understand the values and motivations of potential users and influencers of the Dual Prevention Pill (DPP) in Kenya, South Africa, and Zimbabwe.
This factsheet provides answers to the most frequently asked questions about the Dual Prevention Pill (DPP), including what it is, who might use it, and how it can be rolled out.
We are delighted to share the new and improved AVAC.org! On our new site, you can easily access all the great data, policy analysis, tools and resources that you’ve come to expect from AVAC, including our much-loved infographics, podcasts, Weekly NewsDigest and Pandemic Watch, webinars, research literacy materials and so much more!
The updated AVAC.org also reflects the expanded vision and practice of our dynamic programs. AVAC will always work to accelerate ethical development and equitable delivery of effective HIV prevention options. But, we also know that responding to HIV and preparing for future pandemics requires a comprehensive, integrated, and sustained response that is rights-based, people-centered and evidence-informed.
To AVAC, this means connecting the dots between HIV prevention, sexual and reproductive health and rights, pandemic preparedness, strengthened health systems, research engagement and community leadership. It means recognizing that resilience in global health requires us to confront the threats posed by disparities in access, entrenched stigma, discrimination, criminalizing key populations and inadequate responses to other sexually transmitted infections.
Visit the new AVAC.org for resources, tools and analysis that make these connections as we continue to track and translate the field, including:
And be sure to check out three vital AVAC resources that give you all the information you need on PrEP access, STI vaccine and diagnostics R&D and HIV prevention R&D funding.
We are immensely proud to share these resources with you. We hope these tools and analyses will help to power your advocacy, accelerate ethical development and equitable delivery of effective HIV prevention options, and advance global health equity.
PrEP Tracker data, preparing for new products, the HIV prevention pipeline and our prevention playlist. All that and more in the latest issue of PxWire.
This factsheet provides basic information on sexually transmitted infections (STIs), and a snapshot on the global status of STIs in the context of HIV prevention and global health equity.
Avac Event
On Wednesday, September 6, please make plans to join The Choice Agenda (TCA), the International Network of People Who Use Drugs (INPUD) and our wonderful expert speakers to discuss the health and wellness priorities of people who use/inject drugs, and how these communities (“key populations”) intersect across PrEP research, development, and implementation activities. They will highlight critical gaps in the PrEP agenda, underscore opportunities for improvement, and share strategies for better inclusion, representation and meaningful engagement.
Speakers: John Kimani, Kenya Network of People Who Use Drugs (KeNPUD) Dr. Sunil Solomon, Johns Hopkins University, Ukrainian Provider
** With special thanks to WHO, this webinar will offer simultaneous Ukrainian translation. **
TCA’s invited experts will share their highlights and reflections on the HIV and STI-related science presented at two major global health conferences. These conferences include IAS 2023, taking place in Brisbane, Australia July 23 – 26 and the 2023 STI and HIV World Congress happening in Chicago (United States) from July 24 – July 27.
Speakers include:
Dr. Aniruddha Hazra – University of Chicago
Nyaradzo M Mgodi – University of Zimbabwe
Roger Pebody – NAM, Aidsmap.com
Charlie Peterson – University of Illinois – Chicago
In its 17th annual report, the Resource Tracking for HIV Prevention Research & Development Working Group documents research and development spending for the calendar year 2021. This report also analyzes funding trends spanning 22 years for the following biomedical HIV prevention options: preventive HIV vaccines, microbicides, pre-exposure prophylaxis (PrEP), treatment as prevention (TasP), voluntary medical male circumcision (VMMC), female condoms and prevention of vertical transmission (PVT). More information at hivresourcetracking.org.
May 17, 2023
With several large HIV vaccine trials in the last few years finding no efficacy, the field is in transition. There are diverse ideas in vaccine research, but there’s no clear concept that’s ready to test in a late-phase trial or move towards product development currently. Researchers are back to testing new ideas in early phase research.
In this episode of our Px Pulse podcast, Evolving Strategies for an HIV Vaccine: One researcher explains where the field is going and why?, Dr. Katy Stephenson explores the implications of recent trial results, the big questions driving next generation vaccine development, and new strategies underway in early phase research. Katy is a doctor, a researcher, a professor of medicine at Harvard Medical School, affiliated with Beth Israel Deaconess Medical Center, and part of the Center for Virology and Vaccine Research.